share_log

Rayont Inc- RAYT- Reports 10-Q for the Three -Month Ending September 30, 2022, Financial Results.

Rayont Inc- RAYT- Reports 10-Q for the Three -Month Ending September 30, 2022, Financial Results.

Rayont Inc-RAYT-公佈截至2022年9月30日的三個月的10季度財務業績。
GlobeNewswire ·  2023/01/17 09:06

Palo Alto, California, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC PINK: RAYT), an international personalized natural healthcare company, today reported financial results for the three-month ended September 30, 2022.

加利福尼亞州帕洛阿爾託,2023年1月17日(GLOBE NEWSWIRE)——國際個性化自然醫療保健公司雷昂公司(“Rayont” 或 “公司”)(OTC PINK: RAYT)今天公佈了截至2022年9月30日的三個月的財務業績。

Business Highlights Within the Three-Month ended September 30, 2022:

內部業務亮點 T三個-本月已結束 九月 30,2022:

Ms. Marshini Moodley, CEO and CFO, said, "We recorded an increase in both the revenue and gross profit for the period ended September 30, 2022 compared to same period last year, mainly due to acquisition of the business of No More Knots Pty Ltd, No More Knots (Newmarket) Pty Ltd, No More Knots (Taringa) Pty Ltd, Ipswich Massage Pty Ltd and Tugun Compounding Pharmacy Pty Ltd.

首席執行官兼首席財務官Marshini Moodley女士表示:“與去年同期相比,截至2022年9月30日的期間,我們的收入和毛利均有所增長,這主要是由於收購了No More Knots Pty Ltd、No More Knots(Newmarket)私人有限公司、No More Knots(Taringa)Pty Ltd、Ipswich Massage Pty Ltd和Tugun Compounding Pharmacy 的業務 Pty Ltd.

Three-month Ending September 30, 2022, Financial Results:

T三個-月結束九月 30,2022財務業績:

    Three Months Ended September 30,  
    2022     2021  
Revenues   $ 1,368,677     $ 687,523  
Gross Profit   $ 798,262     $ 358,173  
    T三個已結束的月份九月30  
    2022     2021  
收入   $ 1,368,677     $ 687,523  
毛利   $ 798,262     $ 358,173  

Improved Balance Sheet Results

資產負債表業績改善

      September 30,
2022
      June 30,
2022
 
Cash   $ 28,921     $ 185,782  
Total Assets   $ 8,980,404     $ 14,193,235  
Total Liabilities   $ 2,678,754     $ 9,099,623  
Total Stockholders' Equity   $ 6,301,650     $ 5,093,612  
      九月 30
2022
      6月30日,
2022
 
現金   $ 28,921     $ 185,782  
總資產   $ 8,980,404     $ 14,193,235  
負債總額   $ 2,678,754     $ 9,099,623  
股東權益總額   $ 6,301,650     $ 5,093,612  

Marshini Moodley added, "Our quarterly performance reflecting decreased total asset portfolio and total liabilities mainly as result of the sale of three subsidiaries of the group that included mostly the land, properties and loans related with those properties. Due to that, the working capital is improved as there was a working capital deficit of $83,884 on June 30, 2022 and working capital of $1,730,581 on September 30, 2022. Our cash reserves have decreased due to capital investments and servicing loan interest received to cover different investments done from the Company during the quarter".

Marshini Moodley補充說:“我們的季度業績反映了總資產組合和總負債的減少,這主要是由於出售了該集團的三家子公司,主要包括與這些物業相關的土地、房地產和貸款。因此,由於營運資金赤字爲,營運資金得到改善 $83,884 2022 年 6 月 30 日,營運資金爲 $1,730,581 2022 年 9 月 30 日。我們的現金儲備減少了,這是由於爲支付公司在本季度進行的不同投資而收到的資本投資和還本付息貸款利息”。

Strategies for Growth

增長策略

During this financial year we continue to undertake several key activities aimed to improve the overall performance of Rayont Inc namely:

在本財政年度,我們將繼續開展多項旨在改善Rayont Inc整體業績的關鍵活動,即:

  • Continue to consolidate the operations of Prema Life with that of Tugun Compounding Pharmacy to drive cost reduction and efficiencies across both operations.
  • Launch Health Script telehealth platform for naturopaths globally with key markets focus Australia and the USA.
  • Continue with smaller acquisitions that can contribute to revenue growth and synergies across the group. We expect that the acquisitions made to date will contribute to significant revenue and profit growth this financial year.
  • 繼續將Prema Life的運營與Tugun Compounding Pharmacy的運營合併,以推動這兩項業務的成本降低和效率。
  • 爲全球自然療法者推出Health Script遠程醫療平臺,主要市場集中在澳大利亞和美國。
  • 繼續進行規模較小的收購,以促進整個集團的收入增長和協同效應。我們預計,迄今爲止的收購將有助於本財政年度的顯著收入和利潤增長。

These activities are being worked on and we will communicate their completions as we achieve them.

這些活動正在進行中,我們將在完成這些活動後告知其完成情況。

Disclosure Regarding the Financial Reports Provided in the Form 10-Q

披露 R關於那個 F財務的 R出口 已提供 在 10-Q 表格中

The auditor's review for current version of the Form 10Q has not been completed due to the fact that the valuation report for the acquisition of the business of Ipswich Massage Pty Ltd, Prema Life Pty Ltd and Tugun Compounding Pharmacy Pty Ltd by an independent expert that not been completed. The company is in process of procuring these reports.

審計師對當前版本的10Q表格的審查尚未完成,這是因爲獨立專家收購Ipswich Massage Pty Ltd、Prema Life Pty Ltd和Tugun Compounding Pharmacy Pty Ltd業務的估值報告尚未完成。該公司正在獲取這些報告。

Once the auditor's review is ready, the Company will file an amendment to its Form 10-Q.

審計師的審查準備就緒後,公司將提交其10-Q表的修正案。

About Rayont Inc.

A比賽雷蒙特公司

Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on personalized natural healthcare industry.

Rayont, Inc.(RAYT)是一家自2011年成立以來在美國內華達州註冊的上市公司。2018 年,公司重新定位,專注於個性化自然醫療行業。

Rayont uses scientific tools such as DNA, microbiome, iridology and other tests to personalize diagnoses, prescription and treatments of natural complementary and alternative medicine products, services and treatments to our patients in the markets we operate.

Rayont使用DNA、微生物組、虹膜學和其他測試等科學工具,爲我們運營的市場中的患者提供天然補充和替代藥物產品、服務和治療的個性化診斷、處方和治療。

For further information, please visit 

欲瞭解更多信息,請訪問

SAFE HARBOR

安全港

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

本新聞稿中的某些陳述可能包含1933年《證券法》第175條所指的前瞻性信息,受1934年《證券交易法》第3b-6條的約束,並受這些規則建立的安全港的約束。除事實陳述外,本新聞稿中包含的所有陳述,包括但不限於有關公司未來潛在計劃和目標的陳述,均爲涉及風險和不確定性的前瞻性陳述。無法保證此類陳述會被證明是準確的,其他結果和進一步的事件可能與此類聲明中的預期存在重大差異。未來事件和實際結果可能與前瞻性陳述中闡述、所考慮或所依據的事件和實際結果存在重大差異。

Company Contact:
Investor Relations
ir@rayont.com

公司聯繫人:
投資者關係
ir@rayont.com


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論